In July 2003, Aspreva signed a collaboration agreement with Roche for the exclusive worldwide rights to develop and, upon regulatory approval, commercialize CellCept
for all autoimmune disease applications.
(mycophenolate mofetil) plus low-dose tacrolimus, corticosteroids and IL-2 induction therapy was shown to be the top combination to prevent patients rejecting their new kidney whilst maximising the function and life of the new organ.
Two examples already available are Rapamune and CellCept
, while others are still in the research pipeline.
(mycophenolate mofetil), a drug that prevents rejection of transplants, for secondary-progressive MS WHERE At 2 sites in the U.
Patients were randomly assigned treatment with a combination of either the immunosuppressants cyclosporine, prednisone, CellCept
(mycophenolate mofetil), and Zenapax, or cyclosporine, prednisone, and CellCept
The off-label use of two high-priced agents--the biologic rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan, Roche's MabThera) and the immunosuppressant mycophenolate mofetil (Roche/Galenica's CellCept
, generics)--generated the majority of sales in 2011.
Princeton, NJ, announced it has introduced mycophenolate mofetil capsules and tablets, generic equivalents of CellCept
, in the US, an immunosuppressant used to prevent organ rejection after kidney, liver or heart transplants.
And Roche Holding AG's CellCept
, given to organ transplant patients to prevent rejection, will carry new U.
The rapid growth in production of Cellcept
and Xeloda exemplify this success.
TABLE Characteristics of 3 Patients With Refractory Immune Thrombocytopenic Purpura Pretreatment Case Age/Sex Previous Treatments Platelets/[micro]L 1 49/F Prednisone, splenectomy, IVIC, <10,000 WinRho, cyclosporin A, Cytoxan, Cellcept
2 87/F Prednisone, WinRho, <15,000 vincristine, IVIG 3 75/M Prednisone, IVIG, WinRho <20,000 Posttreatment Duration of Highest Response Case Platelets/[micro]L (months) Retreatment 1 37,000 6 Yes 2 175,000 [less than or equal to]3 No 3 59,000 [less than or equal to]7 No
Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept
in combination therapy.
CLINICAL DATA AND INTERVIEWED THOUGHT LEADERS INDICATE BENLYSTA HAS ADVANTAGES OVER SALES-LEADING CELLCEPT
FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS